. Author manuscript; available in PMC: 2016 Jan 1.

Published in final edited form as: J Clin Gastroenterol. 2015 Jan;49(1):76–83. doi: 10.1097/MCG.0000000000000055

Table 4.

Baseline Self-Efficacy as a Predictor of Ribavirin Nonpersistence

	Baseline to Treatment Week 24

	Unadjusted (N=384)		Adjusted^a (N=384)
	HR (95% CI)	p-value	HR (95% CI)	p-value
Global Self-Efficacy	0.73 (0.59, 0.90)	0.004	0.77 (0.58, 1.03)	0.078
Communication Self-Efficacy	0.83 (0.70, 0.98)	0.026	0.87 (0.73, 1.04)	0.125
Physical Coping Self-Efficacy	0.86 (0.75. 0.98)	0.026	0.93 (0.79, 1.09)	0.380
Psychological Coping Self-Efficacy	0.88 (0.75, 1.03)	0.107	0.97 (0.79, 1.18)	0.745
Adherence Self-Efficacy	0.77 (0.65, 0.91)	0.002	0.78 (0.63, 0.95)	0.013

Note: HR: Hazard Ratio, calculated using Cox Proportional Hazards Model. CI: Confidence Interval.

Model adjusted for age, race, gender, employment status, marital status and baseline depressive symptomatology. Interpretation: when HR < 1, higher self-efficacy was associated with a lower risk of ribavirin nonpersistence.